Polygenic Score (PGS) ID: PGS002238

Predicted Trait
Reported Trait Systolic blood pressure
Mapped Trait(s) systolic blood pressure (EFO_0006335)
Additional Trait Information Used to predict apparent treatment-resistant hypertension
Released in PGS Catalog: July 21, 2022
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name SBP_PRS
Development Method
Name PRS-CS
Parameters p - value threshold, 1e-1
Variants
Original Genome Build hg19
Number of Variants 1,119,444
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000270
Citation (link to publication) Breeyear JH et al. Circ Genom Precis Med (2022)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 58.3%
East Asian: 21.8%
African: 15.1%
Hispanic or Latin American: 3.6%
Additional Asian Ancestries: 0.8%
Additional Diverse Ancestries: 0.4%
627,529 individuals (100%)
Score Development/Training
European: 100%
341,930 individuals (100%)
PGS Evaluation
Not Reported: 33.3%
African: 33.3%
European: 33.3%
3 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST007267
Europe PMC: 30578418
 365,998 individuals European MVP, UKB
GWAS Catalog: GCST007267
Europe PMC: 30578418
 63,490 individuals African unspecified MVP, UKB
GWAS Catalog: GCST007267
Europe PMC: 30578418
 22,802 individuals Hispanic or Latin American MVP, UKB
GWAS Catalog: GCST007267
Europe PMC: 30578418
 4,792 individuals Asian unspecified MVP, UKB
GWAS Catalog: GCST007267
Europe PMC: 30578418
 2,695 individuals Native American MVP, UKB
GWAS Catalog: GCST004385
Europe PMC: 28498854
 31,155 individuals African unspecified NR
GWAS Catalog: GCST005979
Europe PMC: 29403010
 136,597 individuals East Asian BBJ
Score Development/Training
Study Identifiers Sample Numbers Sample Ancestry Cohort(s) Phenotype Definitions & Methods Age of Study Participants Participant Follow-up Time Additional Ancestry Description Additional Sample/Cohort Information
— 341,930 individuals,
45.0 % Male samples
 European UKB — Mean = 56.64 years — Multi-Ancestry —

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM012729 PSS009511|
African Ancestry|
10,052 individuals
 PGP000270 |
Breeyear JH et al. Circ Genom Precis Med (2022)
 Reported Trait: Apparent Treatment-Resistant Hypertension OR: 1.05 [0.95, 1.17] AUROC: 0.666 [0.637, 0.683] — age, age^2, bmi, sex, top 10 principal components of ancestry —
PPM012730 PSS009512|
European Ancestry|
57,090 individuals
 PGP000270 |
Breeyear JH et al. Circ Genom Precis Med (2022)
 Reported Trait: Apparent Treatment-Resistant Hypertension OR: 1.11 [1.06, 1.17] AUROC: 0.68 [0.669, 0.689] — age, age^2, bmi, sex, top 10 principal components of ancestry —
PPM012731 PSS009510|
Ancestry Not Reported|
4,407 individuals
 PGP000270 |
Breeyear JH et al. Circ Genom Precis Med (2022)
 Reported Trait: Apparent Treatment-Resistant Hypertension OR: 1.1 [1.05, 1.15] AUROC: 0.682 [0.67, 0.687] — age, age^2, bmi, sex, top 10 principal components of ancestry —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS009511 Apparent Treatment-Resistant Hypertension —
[
  • 574 cases
  • , 4,452 controls
]
,
37.0 % Male samples
 Mean = 50.6 years African American or Afro-Caribbean African American, Non-Hispanic Black BioVU —
PSS009511 Apparent Treatment-Resistant Hypertension —
[
  • 574 cases
  • , 4,452 controls
]
,
37.0 % Male samples
 Mean = 50.6 years African American or Afro-Caribbean African American, Non-Hispanic Black BioVU Multi-Ancestry analysis
PSS009512 Apparent Treatment-Resistant Hypertension —
[
  • 2,961 cases
  • , 25,584 controls
]
,
46.0 % Male samples
 Mean = 58.58 years European European, Non-Hispanic White BioVU —
PSS009512 Apparent Treatment-Resistant Hypertension —
[
  • 2,961 cases
  • , 25,584 controls
]
,
46.0 % Male samples
 Mean = 58.58 years European European, Non-Hispanic White BioVU Multi-Ancestry analysis
PSS009510 Apparent Treatment-Resistant Hypertension —
[
  • 106 cases
  • , 4,301 controls
]
 — Not reported — BioVU Multi-Ancestry analysis